Insmed Inc (INSM)vsSpero Therapeutics Inc (SPRO)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SPRO
Spero Therapeutics Inc
$2.41
+1.69%
HEALTHCARE · Cap: $132.40M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1396% more annual revenue ($606.42M vs $40.55M). INSM leads profitability with a -2.1% profit margin vs -108.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
SPRO
Avoid25
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Earnings expanding 75.3% YoY
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Smaller company, higher risk/reward
ROE of -95.3% — below average capital efficiency
Revenue declined 59.6%
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SPRO
The strongest argument for SPRO centers on EPS Growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SPRO
The primary concerns for SPRO are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
SPRO carries more volatility with a beta of 1.53 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
SPRO generates stronger free cash flow (17M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Spero Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?